Skip to contentA
Arcutis Biotherapeutics, Inc.
A
ARQTArcutis Biotherapeutics, Inc. Q1 2022 · 10-Q
Revenue$0.00$0.00no prior Q1 2021 on file Net Income-$64.32M-$64.32MN/M vs Q1 2021 EPS Diluted-$1.27-$1.27N/M vs Q1 2021 Operating Income-$62,628,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
Free Cash Flowderived-$57,099,000N/M ended Mar 31, 2022 · filed May 5, 2022 · 35 d after period end